1443248-72-3

Upstream product

• 1443242-59-8 2,2,2-trifluoro-N-((1S,4R)-4-hydroxy-1,2,3,4-tetrahydro-naphthalen-1-yl)-acetamide 
• 1443242-57-6 2,2,2-trifluoro-N-[(S)‐4‐carbonyl-1,2,3,4-tetrahydronaphthalen-1-yl]acetamide 
• 1351997-20-0 (1R,4S)-aminoN-(S)-4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-ol 
• 1443248-70-1 3-(2-chloro-phenyl)-6-fluoro-[1,2,4]triazolo[4,3-a]pyridine 
• 1443248-68-7 2-chloro-benzoic acid N'-(5-fluoro-pyridin-2-yl)-hydrazide 
• 609-65-4 o-chlorobenzoyl chloride 
• 23357-52-0 (S)-1,2,3,4-tetrahydronapht-1-yl-amine 

Downstream Products

• 1443247-49-1 1-[5-tert-butyl-2-(2-hydroxy-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-(2-chloro-phenyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea 

Relevant academic research and scientific papers

KINASE INHIBITORS

Compounds of formula (I) or a pharmaceutically acceptable salt thereof: wherein R2, W, A, Y and R1 are as defined in the specification, are p38 MAPK inhibitors, useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.

KINASE INHIBITORS

Compounds of formula (I): wherein R2, W, A, Y, and R1 are as defined in the specification, and pharmaceutically acceptable salts thereof, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.